BioAge Labs Schedules June Fireside Chats at Jefferies and Goldman Healthcare Conferences
BioAge Labs will present at Jefferies Healthcare Conference June 3–4 in New York and Goldman Sachs Healthcare Conference June 8–10 in Miami Beach, with CFO Dov Goldstein and CSO BJ Sullivan hosting fireside chats and one-on-ones. Its lead candidate BGE-102 enters Phase 2 cardiovascular trials by year-end 2026.
1. Conference Participation
BioAge Labs will participate in the Jefferies Healthcare Conference in New York on June 3–4, featuring a fireside chat on June 4 at 3:45–4:15 PM EDT and one-on-one meetings with investors. A live webcast will be available, with replays archived for 30 days on the company’s website.
2. Goldman Sachs Engagement
The company’s leadership team will also engage at the Goldman Sachs Healthcare Conference in Miami Beach on June 8–10, hosting a fireside chat on June 8 from 2:40–3:15 PM EDT and follow-up meetings. Webcast registration details are provided for live and on-demand access.
3. Pipeline Milestones
BioAge’s lead candidate BGE-102 has completed Phase 1 SAD/MAD trials showing significant reductions in hsCRP and other inflammatory biomarkers. The company anticipates Phase 2 cardiovascular risk proof-of-concept data by year-end 2026 and Phase 1b/2a diabetic macular edema data in mid-2027.